Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?
Bayer Aktiengesellschaft is a member of our Medical group, which includes 997 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Bayer Aktiengesellschaft is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for BAYRY's full-year earnings has moved 9.4% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, BAYRY has gained about 45.3% so far this year. Meanwhile, stocks in the Medical group have lost about 5.8% on average. This means that Bayer Aktiengesellschaft is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is BioCryst Pharmaceuticals (BCRX). The stock is up 43.5% year-to-date.
For BioCryst Pharmaceuticals, the consensus EPS estimate for the current year has increased 359.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Bayer Aktiengesellschaft belongs to the Large Cap Pharmaceuticals industry, a group that includes 11 individual stocks and currently sits at #41 in the Zacks Industry Rank. Stocks in this group have lost about 4.3% so far this year, so BAYRY is performing better this group in terms of year-to-date returns.
On the other hand, BioCryst Pharmaceuticals belongs to the Medical - Drugs industry. This 161-stock industry is currently ranked #56. The industry has moved -0.9% year to date.
Investors interested in the Medical sector may want to keep a close eye on Bayer Aktiengesellschaft and BioCryst Pharmaceuticals as they attempt to continue their solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report
BioCryst Pharmaceuticals, Inc. (BCRX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
ASML: Q2 Earnings Snapshot
DR VELDHOVEN, Netherlands (AP) — DR VELDHOVEN, Netherlands (AP) — ASML Holding NV (ASML) on Wednesday reported second-quarter net income of $1.79 billion. The Dr Veldhoven, Netherlands-based company said it had profit of $4.55 per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $5.94 per share. The equipment supplier to semiconductor makers posted revenue of $8.73 billion in the period, which beat Street forecasts. Three analysts surveyed by Zacks expected $8.55 billion. ASML shares have increased 19% since the beginning of the year. The stock has declined 23% in the last 12 months. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on ASML at Sign in to access your portfolio
Yahoo
7 hours ago
- Yahoo
Luminar Technologies, Inc. (LAZR) Gains As Market Dips: What You Should Know
Luminar Technologies, Inc. (LAZR) closed the most recent trading day at $2.85, moving +2.52% from the previous trading session. This change outpaced the S&P 500's 0.4% loss on the day. Meanwhile, the Dow lost 0.98%, and the Nasdaq, a tech-heavy index, added 0.18%. Prior to today's trading, shares of the company had lost 6.87% lagged the Auto-Tires-Trucks sector's gain of 0.64% and the S&P 500's gain of 4.97%. The investment community will be closely monitoring the performance of Luminar Technologies, Inc. in its forthcoming earnings report. The company is scheduled to release its earnings on August 12, 2025. The company is expected to report EPS of -$1.19, up 55.93% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $16.72 million, up 1.64% from the prior-year quarter. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$4.29 per share and revenue of $86.64 million, indicating changes of +53.57% and +14.91%, respectively, compared to the previous year. Investors should also pay attention to any latest changes in analyst estimates for Luminar Technologies, Inc. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Right now, Luminar Technologies, Inc. possesses a Zacks Rank of #3 (Hold). The Automotive - Original Equipment industry is part of the Auto-Tires-Trucks sector. With its current Zacks Industry Rank of 178, this industry ranks in the bottom 28% of all industries, numbering over 250. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow LAZR in the coming trading sessions, be sure to utilize Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Luminar Technologies, Inc. (LAZR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
Canopy Growth Corporation (CGC) Dips More Than Broader Market: What You Should Know
In the latest close session, Canopy Growth Corporation (CGC) was down 6.84% at $1.09. The stock's change was less than the S&P 500's daily loss of 0.4%. Meanwhile, the Dow experienced a drop of 0.98%, and the technology-dominated Nasdaq saw an increase of 0.18%. Heading into today, shares of the company had lost 19.31% over the past month, lagging the Medical sector's loss of 1.56% and the S&P 500's gain of 4.97%. The investment community will be paying close attention to the earnings performance of Canopy Growth Corporation in its upcoming release. The company's upcoming EPS is projected at -$0.11, signifying a 70.27% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $48.08 million, down 0.64% from the year-ago period. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.43 per share and a revenue of $199.33 million, indicating changes of +85.57% and +3.12%, respectively, from the former year. It's also important for investors to be aware of any recent modifications to analyst estimates for Canopy Growth Corporation. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 5.69% lower. Canopy Growth Corporation is currently sporting a Zacks Rank of #4 (Sell). The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 141, finds itself in the bottom 43% echelons of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Canopy Growth Corporation (CGC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
